AstraZeneca: new study launched in lung cancer
(CercleFinance.com) - On Friday AstraZeneca and its Japanese partner Daiichi Sankyo announced the start of a new phase 3 trial of their datopotamab antibody conjugate deruxtecan, this time in the treatment of a form of lung cancer with a high risk of relapse.
The trial is designed to measure the efficacy and safety of the drug in combination with rilvegostomig, another AstraZeneca compound, compared with standard therapy in 660 patients with stage 1 non-small cell lung cancer with tumor DNA and other pathology, and after surgery.
The companies say that this is a category of patients with a high risk of recurrence.
AstraZeneca and Daiichi Sankyo note that datopotamab deruxtecan is currently in eight Phase 3 trials in breast cancer and five studies in breast cancer, as monotherapy or in combination with other anti-cancer drugs.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The trial is designed to measure the efficacy and safety of the drug in combination with rilvegostomig, another AstraZeneca compound, compared with standard therapy in 660 patients with stage 1 non-small cell lung cancer with tumor DNA and other pathology, and after surgery.
The companies say that this is a category of patients with a high risk of recurrence.
AstraZeneca and Daiichi Sankyo note that datopotamab deruxtecan is currently in eight Phase 3 trials in breast cancer and five studies in breast cancer, as monotherapy or in combination with other anti-cancer drugs.
Copyright (c) 2025 CercleFinance.com. All rights reserved.